CAS 1884712-47-3

cpi-637

Description:

CPI-637, identified by its CAS number 1884712-47-3, is a small molecule that functions primarily as a selective inhibitor of certain enzymes involved in the regulation of cellular processes. It is part of a class of compounds that target specific pathways, often related to cancer and other diseases. The compound exhibits a unique chemical structure that allows it to interact with its biological targets with high specificity, potentially leading to reduced side effects compared to less selective agents. CPI-637 has been studied for its therapeutic potential, particularly in oncology, where it may help in the modulation of tumor growth and proliferation. Its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion, are critical for determining its efficacy and safety profile in clinical settings. As research continues, the understanding of CPI-637's mechanism of action and its role in therapeutic regimens is expected to evolve, contributing to the development of targeted therapies in modern medicine.

Formula: C₂₂H₂₂N₆O

Synonyms:

• 2H-1,5-Benzodiazepin-2-one, 1,3,4,5-tetrahydro-4-methyl-6-[1-methyl-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-5-yl]-, (4R)-
• CPI-637;CPI 637;CPI637
• CPI-637 >=98% (HPLC)

CPI-637

CAS: 1884712-47-3

Formula: C₂₂H₂₂N₆O

Purity: %

Color and Shape: Solid

Molecular weight: 386.4497

Ref: IN-DA00ABS2

CPI-637

CAS: 1884712-47-3

CPI-637

Purity: ≥98%

Molecular weight: 386.45g/mol

Ref: 54-BUP12484

CPI-637

CAS: 1884712-47-3

CPI-637 is a selective and cell-active benzodiazepinone CBP/EP300 bromodomain inhibitor.

Formula: C₂₂H₂₂N₆O

Purity: 99.89% - 99.95%

Color and Shape: Solid

Molecular weight: 386.45

Ref: TM-T6811

CPI-637

CAS: 1884712-47-3

CPI-637 is a potential drug for the treatment of prostate cancer. It is a small molecule that binds to the bromodomain, which is an important cellular protein that regulates transcriptional regulation. Bromodomains are found in many proteins and are known to be involved in many cellular processes and cancers. CPI-637 has been shown to inhibit the expression of genes associated with prostate cancer, HIV infection, and carcinogenesis. This agent does not bind to DNA but binds to histone h3 at a specific site called the response element-binding protein (RBP), which inhibits gene expression by binding to the RBP.

Formula: C₂₂H₂₂N₆O

Purity: Min. 95%

Molecular weight: 386.45 g/mol

Ref: 3D-JAD71247